Live Webcast Beginning at 8am Eastern Time on May 28th
TORONTO, May 27, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced
today that it will host an Investor Day on Wednesday, May 28th in New
York City. An industry key opinion leader, Constantine G. Lyketsos,
MD, and Transition's executive management team will offer insights into
Transition's lead drug candidate, ELND005, and its potential role in
the treatment of Alzheimer's disease.
The presentations, followed by a question-and-answer session, will be
webcast live beginning at 8am Eastern Time. The webcast and
accompanying presentation materials will be accessible live and
archived on the Media Center section of the Transition corporate
website at www.transitiontherapeutics.com.
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. The Company's lead CNS drug
candidate is ELND005 for the treatment of Alzheimer's disease and Down
syndrome. Transition's lead metabolic drug candidate is TT-401
(LY2944876) for the treatment of type 2 diabetes and accompanying
obesity. The Company's shares are listed on the NASDAQ under the symbol
"TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials and potential efficacy of its products.
These statements are based upon the current expectations and beliefs of
Transition's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's
quarterly and annual filings with the Canadian commissions.
SOURCE: Transition Therapeutics Inc.
For further information:
For further information on Transition, visit www.transitiontherapeutics.com or contact:
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223